Pliant Therapeutics (PLRX) Competitors $14.37 +0.65 (+4.74%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PLRX vs. EWTX, JANX, XENE, MRUS, ACAD, TWST, MOR, VCEL, SWTX, and ZLABShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Twist Bioscience (TWST), MorphoSys (MOR), Vericel (VCEL), SpringWorks Therapeutics (SWTX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Edgewise Therapeutics Janux Therapeutics Xenon Pharmaceuticals Merus ACADIA Pharmaceuticals Twist Bioscience MorphoSys Vericel SpringWorks Therapeutics Zai Lab Edgewise Therapeutics (NASDAQ:EWTX) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation. Does the MarketBeat Community believe in EWTX or PLRX? Pliant Therapeutics received 41 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 73.91% of users gave Edgewise Therapeutics an outperform vote. CompanyUnderperformOutperformEdgewise TherapeuticsOutperform Votes3473.91% Underperform Votes1226.09% Pliant TherapeuticsOutperform Votes7574.26% Underperform Votes2625.74% Does the media prefer EWTX or PLRX? In the previous week, Edgewise Therapeutics had 14 more articles in the media than Pliant Therapeutics. MarketBeat recorded 16 mentions for Edgewise Therapeutics and 2 mentions for Pliant Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.61 beat Pliant Therapeutics' score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, EWTX or PLRX? Edgewise Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Which has preferable valuation & earnings, EWTX or PLRX? Edgewise Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$100.16M-$1.50-20.11Pliant Therapeutics$1.58M553.46-$161.34M-$3.34-4.30 Is EWTX or PLRX more profitable? Edgewise Therapeutics' return on equity of -26.83% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -26.83% -25.67% Pliant Therapeutics N/A -48.91%-41.09% Do analysts recommend EWTX or PLRX? Edgewise Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 43.08%. Pliant Therapeutics has a consensus price target of $40.50, indicating a potential upside of 181.84%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Pliant Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do institutionals & insiders have more ownership in EWTX or PLRX? 97.3% of Pliant Therapeutics shares are owned by institutional investors. 24.1% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryPliant Therapeutics beats Edgewise Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$834.92M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-4.3010.79135.3117.54Price / Sales553.46287.861,215.74139.37Price / CashN/A56.6540.5837.95Price / Book1.825.394.884.92Net Income-$161.34M$152.04M$118.89M$225.78M7 Day Performance1.20%-4.32%16.99%-1.58%1 Month Performance16.64%2.80%16.58%6.67%1 Year Performance-12.75%17.30%35.26%22.48% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics3.3301 of 5 stars$14.37+4.7%$40.50+181.8%-14.3%$834.92M$1.58M-4.3090EWTXEdgewise Therapeutics2.8288 of 5 stars$34.58+25.2%$42.33+22.4%+313.9%$3.27BN/A-22.8560Analyst ForecastShort Interest ↓News CoverageGap UpHigh Trading VolumeJANXJanux Therapeutics3.5946 of 5 stars$62.14+1.7%$89.90+44.7%+474.8%$3.26B$13.05M-52.2330XENEXenon Pharmaceuticals2.7658 of 5 stars$40.96+2.3%$56.90+38.9%-0.3%$3.12B$9.43M-14.20251MRUSMerus2.9299 of 5 stars$42.83flat$85.64+99.9%+77.9%$2.93B$43.95M-10.8437ACADACADIA Pharmaceuticals3.9246 of 5 stars$17.44+1.0%$25.60+46.8%-39.1%$2.90B$726.44M22.13510TWSTTwist Bioscience2.8772 of 5 stars$48.87+2.9%$51.90+6.2%+39.8%$2.90B$312.97M-13.19990MORMorphoSys0.0797 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730VCELVericel0.903 of 5 stars$57.54+0.1%$59.71+3.8%+54.0%$2.84B$226.84M957.83300Positive NewsSWTXSpringWorks Therapeutics1.9318 of 5 stars$38.16-0.4%$69.50+82.1%+11.0%$2.84B$5.45M-9.87305Positive NewsZLABZai Lab2.5215 of 5 stars$26.03-1.1%$55.00+111.3%-10.1%$2.83B$355.75M-9.512,175 Related Companies and Tools Related Companies EWTX Alternatives JANX Alternatives XENE Alternatives MRUS Alternatives ACAD Alternatives TWST Alternatives MOR Alternatives VCEL Alternatives SWTX Alternatives ZLAB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PLRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLRX Stock Alerts